InflaRx (IFRX) Stock Price, News & Analysis

Company Overview

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes. In addition to its lead program, InflaRx is developing complementary C5a receptor antagonists and novel anti‐inflammatory antibodies in earlier stages of development. The company’s research efforts leverage proprietary antibody engineering and target validation platforms to identify and optimize molecules with high specificity and favorable safety profiles.

Founded in 2007, InflaRx is headquartered in Jena, Germany, with a subsidiary in Bernardsville, New Jersey. The company maintains a global footprint by collaborating with academic institutions, contract research organizations and key opinion leaders across Europe and North America. InflaRx completed its initial public offering on the Nasdaq Global Market in 2017, reflecting its commitment to advancing innovative therapies from bench to bedside.

Under the leadership of Chief Executive Officer Michael Ernst, M.D., InflaRx is supported by a management team with extensive experience in immunology, drug development and commercial strategy. The company continues to expand its clinical development capabilities as it works toward regulatory milestones and potential partnerships to bring its anti‐C5a therapies to patients worldwide.

Key Stats

• Today's Range: $1.46 to $1.72
• 50-Day Range: $0.80 to $1.75
• 52-Week Range: $0.71 to $2.82
• Volume: 184,357 shs
• Average Volume: 455,547 shs
• Market Capitalization: $116.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.20
• Consensus Rating: Buy

InflaRx Stock Analysis - MarketRank™

InflaRx scored higher than 60% of companies evaluated by MarketBeat, and ranked 435th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

InflaRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

InflaRx has a consensus price target of $6.20, representing about 305.2% upside from its current price of $1.53.

Amount of Analyst Coverage

InflaRx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for InflaRx are expected to decrease in the coming year, from ($1.04) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InflaRx is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InflaRx is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InflaRx has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.35% of the outstanding shares of InflaRx have been sold short.

Short Interest Ratio / Days to Cover

InflaRx has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InflaRx has recently decreased by 3.77%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InflaRx does not currently pay a dividend.

Dividend Growth

InflaRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.35% of the outstanding shares of InflaRx have been sold short.

Short Interest Ratio / Days to Cover

InflaRx has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InflaRx has recently decreased by 3.77%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.05

News Sentiment

InflaRx has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for InflaRx this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

3 people have added InflaRx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InflaRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IFRX Stock Analysis - Frequently Asked Questions

How have IFRX shares performed this year?

InflaRx's stock was trading at $2.47 on January 1st, 2025. Since then, IFRX stock has decreased by 38.1% and is now trading at $1.53.

How were InflaRx's earnings last quarter?

InflaRx N.V. (NASDAQ:IFRX) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.24) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.24). The firm earned $0.05 million during the quarter, compared to analyst estimates of $0.02 million.

When did InflaRx IPO?

InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Who are InflaRx's major shareholders?

Top institutional investors of InflaRx include 683 Capital Management LLC (3.69%), Raymond James Financial Inc. (0.79%), Adage Capital Partners GP L.L.C. (0.49%) and OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.22%).

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include G1 Therapeutics (GTHX), Xeris Biopharma (XERS), Bristol Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IFRX
• CIK: 1708688
• Web: www.inflarx.de
• Phone: 493641508180
• Fax: 49-36-4150-8181
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InflaRx: $6.20
• High Price Target: $10.00
• Low Price Target: $2.00
• Potential Upside/Downside: +264.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.85 million
• Net Margins: N/A
• Pretax Margin: -27,386.74%
• Return on Equity: -71.76%
• Return on Assets: -57.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.10
• Quick Ratio: 3.78

Sales & Book Value

• Annual Sales: $162.83 thousand
• Price / Sales: 700.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.13 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 67,133,000
• Free Float: 56,190,000
• Market Cap: $114.13 million
• Optionable: Optionable
• Beta: 1.43